HC Wainwright & Co. Maintains Buy on Upstream Bio, Lowers Price Target to $18
Benzinga Newsdesk 1 hour ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Matthew Caufield maintains Upstream Bio (NASDAQ:UPB) with a Buy and lowers the price target from $36 to $18.
HC Wainwright & Co. analyst Matthew Caufield maintains Upstream Bio (NASDAQ:UPB) with a Buy and lowers the price target from $36 to $18.